# ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

> **NCT01777152** · PHASE3 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 452 (actual)

## Conditions studied

- Anaplastic Large-Cell Lymphoma
- Non-Hodgkin Lymphoma
- T-Cell Lymphoma

## Interventions

- **DRUG:** brentuximab vedotin
- **DRUG:** doxorubicin
- **DRUG:** prednisone
- **DRUG:** vincristine
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT01777152
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-31
- **Primary completion:** 2018-08-15
- **Final completion:** 2020-10-02
- **Target enrollment:** 452 (ACTUAL)
- **Last updated:** 2021-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777152, "ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01777152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*